Related Experiment Videos
Outcome of specific COX-2 inhibition in rheumatoid arthritis
1Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas 75235-8884, USA.
Abstract:
We reviewed data suggesting the hypothesis that specific inhibition of the inducible isoform of cyclooxygenase, COX-2, would provide therapeutic benefit in patients with rheumatoid arthritis (RA) with less gastrointestinal toxicity and presented the results of a therapeutic trial to test this hypothesis. Various doses of the selective COX-2 inhibitor, celecoxib, or placebo were used to treat patients with RA in a 4 week, double blind, placebo controlled trial. Celecoxib provided significant improvement in patient global assessment, morning stiffness, and the number of painful and tender joints compared with placebo. In addition, the number of withdrawals in celecoxib treated patients was significantly less than in the placebo group. No significant adverse events and no difference in the total number of adverse events were noted between the placebo and celecoxib groups. At the doses employed, celecoxib inhibited only COX-2 and not COX-1. Specific COX-2 inhibition with celecoxib causes significant improvement in the signs and symptoms of RA.
Insights
Selective inhibition of cyclooxygenase-2 (COX-2) with celecoxib effectively treated rheumatoid arthritis (RA) symptoms. This COX-2 inhibitor demonstrated significant symptom improvement with no increase in adverse events compared to placebo.
Area of Science:
- Rheumatology
- Pharmacology
- Biochemistry
Background:
- Rheumatoid arthritis (RA) is a chronic inflammatory disease.
- Current treatments carry risks of gastrointestinal toxicity.
- Cyclooxygenase-2 (COX-2) specific inhibition is hypothesized to reduce RA symptoms with fewer side effects.
Purpose of the Study:
- To test the hypothesis that selective COX-2 inhibition provides therapeutic benefit in RA patients.
- To evaluate the efficacy and safety of celecoxib, a selective COX-2 inhibitor, in treating RA.
Main Methods:
- A 4-week, double-blind, placebo-controlled trial was conducted.
- Patients with RA received various doses of celecoxib or placebo.
- Outcomes measured included patient global assessment, morning stiffness, joint pain, and adverse events.
Main Results:
- Celecoxib significantly improved patient global assessment, reduced morning stiffness, and decreased painful and tender joints compared to placebo.
- Fewer patients withdrew from the celecoxib group than the placebo group.
- No significant adverse events were observed, and the total number of adverse events did not differ between groups.
Conclusions:
- Specific COX-2 inhibition with celecoxib offers significant improvement in RA signs and symptoms.
- Celecoxib demonstrates a favorable safety profile with no increased gastrointestinal toxicity compared to placebo at the tested doses.
- Selective COX-2 inhibition is a viable therapeutic strategy for rheumatoid arthritis.